Table 1.

Summary of Discontinuation of Biologics Among Patients with Severe Asthma

Biologic	Patient Number Discontinued/Continued	Study Design	Main Results	References
Omalizumab	88/88	Randomized, placebo-controlled, double-blind trial	An increase in the rate of asthma exacerbations by 20.0%.	[19]
Omalizumab	49/0	Non-controlled, observational	The rate of maintained asthma control, defined as patients without exacerbations, were 75.5% at 1 year and 60% at 4 years.	[20]
Mepolizumab	27/0	Non-controlled, observational	Worsening of asthma symptoms (mean increase in ACQ, 0.59 points).	[21]
Mepolizumab	592/0	Non-controlled, observational	Deterioration of asthma symptoms (mean increase in ACQ, 0.35 points).	[22]
Mepolizumab	151/144	Randomized, placebo-controlled, double-blind trial	An increase rate of significant exacerbations by 14%, but the rate of exacerbations requiring ED visit and hospitalization was not elevated.	[23]
Omalizumab Dupilumab Mepolizumab Benralizumab Reslizumab	1247/1247	Controlled (propensity score matched), Observational	No risk of asthma exacerbation requiring ED visit or administration of systemic corticosteroid.	[24]

Abbreviations: ACQ, asthma control questionnaire; ED, emergency department.